LPL rs328: Understanding the S447X Genetic Variant
The rs328 variant in the LPL gene, commonly known as S447X, results in a truncated version of the lipoprotein lipase enzyme. This genetic change is frequently studied for its association with improved triglyceride clearance and potentially favorable lipid profiles.
What each genotype means
Typical LPL activity
This is the most common genotype for this variant. Research indicates this version of the LPL gene is associated with standard lipoprotein lipase function in the general population.
This is the most frequent genotype observed across most global populations.
Modified lipid metabolism
Carrying one copy of the G allele (also known as S447X or S474X) is associated with variations in triglyceride and HDL cholesterol levels. Studies suggest this variant may influence how efficiently your body clears triglycerides from the blood, though individual outcomes vary based on diet and other genetic factors.
This heterozygous genotype is found at varying frequencies globally, with the G allele being relatively common in many populations.
Altered triglyceride clearance
Carrying two copies of the G allele (S447X) is associated with significant changes in lipid metabolism, often linked to lower triglyceride levels and higher HDL cholesterol. While this variant is a premature stop codon, it has been studied for its potential role in lipid profile regulation; please discuss your lipid panel results with your clinician to understand how this relates to your cardiovascular health.
This homozygous genotype is less common than the C/C or C/G genotypes in most populations.
What is the rs328 Variant?
The rs328 variant is a single-nucleotide polymorphism (SNP) located within the LPL gene, which provides instructions for making the lipoprotein lipase enzyme. In this specific variant, a change in the DNA sequence replaces the amino acid serine at position 447 with a stop signal. This premature stop codon results in a protein that is two amino acids shorter than the standard version. Because of this truncation, the variant is widely referred to in scientific literature as S447X. While it is a common genetic change, it is distinct from rare mutations that cause complete loss of enzyme function. Instead, researchers have long investigated whether this specific truncation might actually enhance the enzyme's activity, leading to its classification in some studies as a potential gain-of-function variant.
The Role of the LPL Gene
The LPL gene encodes lipoprotein lipase, a critical enzyme that acts as a gatekeeper for lipid metabolism in the body. Its primary function is to break down triglycerides—the main components of body fat—found in triglyceride-rich lipoproteins like VLDL and chylomicrons. By hydrolyzing these fats, the enzyme releases fatty acids that can be used by tissues for energy or stored for later use. This process is essential for maintaining healthy levels of circulating fats in the blood. When LPL functions efficiently, it helps clear triglycerides from the bloodstream and contributes to the maturation of HDL cholesterol, often called 'good' cholesterol. Because of its central role in clearing fats, variations in the LPL gene are frequently studied to understand how they influence an individual's lipid profile and overall cardiovascular risk.
Research Associations and Evidence
Scientific research has consistently associated the S447X variant with a more favorable lipid profile, characterized by lower plasma triglyceride levels and higher HDL cholesterol concentrations. Many studies suggest that carriers of this variant may have a reduced risk of coronary artery disease. However, the strength of this association can vary significantly depending on the population being studied. For instance, research using data from the Jackson Heart Study has indicated that the biological impact of the S447X variant may be less pronounced in individuals of African ancestry compared to those of European ancestry. This suggests that other genetic factors or environmental influences may interact with the variant to modulate its effects. While the evidence points toward a protective role, the clinical significance is considered limited, and it is not used as a standalone diagnostic tool for heart disease.
What You Can Do With This Information
Understanding your genetic variants can be an interesting way to learn about your biological predispositions, but it is important to maintain perspective. The rs328 variant is just one of many factors that influence your lipid levels and cardiovascular health. Diet, physical activity, smoking status, and other genetic markers play significant roles in determining your overall health profile. If you have received information about your LPL genotype, you should view it as a single piece of a much larger puzzle. This information is not a medical diagnosis and cannot predict your future health outcomes with certainty. If you are concerned about your cholesterol or triglyceride levels, the most effective approach is to consult with a healthcare professional. They can interpret your results in the context of your full medical history and provide guidance on lifestyle changes or clinical interventions that are appropriate for you.
How common is this variant?
The rs328 variant is common, with a minor allele frequency typically ranging between 0.15 and 0.20 across many populations, though frequencies can vary by ancestry.
Frequently asked questions
Is the LPL S447X variant a disease-causing mutation?
No, the S447X variant is generally considered a common, functional polymorphism rather than a disease-causing mutation. In fact, it is often associated with a more favorable lipid profile and a potential reduction in cardiovascular risk.
Does having the S447X variant mean I don't need to worry about my cholesterol?
Absolutely not. While this variant is associated with healthier lipid levels, it does not guarantee protection against heart disease. Lifestyle factors like diet and exercise remain the most important tools for managing your cholesterol.
Can I use this genetic information to change my medication?
No. You should never change or stop any medication based on genetic test results without first consulting your doctor or pharmacist. Genetic variants are only one factor in how your body responds to treatment.
Why do some studies show different results for this variant?
Genetic associations can vary between populations due to differences in genetic background and environmental factors. What is observed in one group may not be as strong or consistent in another, which is why scientific findings are often nuanced.
Sources & further reading
Educational information only, last refreshed 10/20/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs328?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in LPL
Missense variant in the lipoprotein lipase gene (Asn291Ser) associated with altered lipid profiles, increased risk of ischemic heart disease, and multivariate aging-related healthspan traits.
A functional gain-of-function variant in the LPL gene that disrupts a microRNA-410 seed site, leading to increased LPL expression, lower plasma triglycerides, higher HDL cholesterol, and potential protective effects against hepatocellular carcinoma in specific clinical contexts.
A common variant in the LPL gene that helps lower triglyceride levels and provides protection against heart disease.
This variant in the lipoprotein lipase gene is studied for its interaction with diet and lifestyle interventions in the context of obesity management.